Q-omics provides the consensus-scored ACTBP2 profile across patient tissues and cancer cell-line models. ACTBP2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ACTBP2 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, ACTBP2 RNA expression shows 16,584 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, HNSC, and ACC as cancer lineages where ACTBP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACTBP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACTBP2 survival associations across molecular data types. ACTBP2 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACTBP2 RNA expression–survival associations across cancer types. High ACTBP2 expression shows unfavorable associations in UVM, ACC, KICH, MESO and LUAD, but favorable associations in KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ACTBP2 RNA expression.
This table summarizes ACTBP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ACTBP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACTBP2 shows lower tumor expression in BLCA and higher tumor expression in HNSC, COAD, BRCA, CHOL and LIHC. The HNSC box plot shows higher ACTBP2 RNA expression in tumor versus normal tissue (log2 FC = +0.501, t-test p < 0.001).
This table shows molecular features associated with ACTBP2 in patient tissues and cancer cell lines. In patient samples, ACTBP2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
